CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
暂无分享,去创建一个
F. Prósper | M. Juan | B. Paiva | J. Lasarte | M. E. Calleja-Cervantes | J. San-Miguel | A. Vilas-Zornoza | M. Pascal | D. Alignani | M. Hernaez | Á. Urbano-Ispizua | C. Fernández de Larrea | S. Inogés | T. Lozano | B. Martín-Antonio | A. Oliver-Caldés | M. Español-Rego | A. Alfonso-Pierola | M. Viguria | J. R. Rodríguez-Madoz | P. Rodríguez-Otero | M. Redondo | Paula Rodriguez-Marquez | Angel Martin-Mallo | Cristina Calviño | Candela Ceballos | Rebeca Martinez-Turrillas | Patricia Jauregui | G. Serrano | M. Palacios-Berraquero | Saray Rodríguez-Díaz | A. López-Díaz de Cerio | Patxi San Martin-Uriz
[1] W. Wang,et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results , 2023, Journal of the Neurological Sciences.
[2] S. Usmani,et al. Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. , 2021, Cancer discovery.
[3] Gregory M. Chen,et al. Integrative bulk and single-cell profiling of pre-manufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. , 2021, Cancer discovery.
[4] Jin-Yuan Ho,et al. Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo , 2021, Molecular therapy. Methods & clinical development.
[5] S. Shen-Orr,et al. Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response , 2021, Molecular Cancer Therapeutics.
[6] A. Rosenwald,et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma , 2021, Nature Medicine.
[7] D. Miklos,et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.
[8] Michael R. Green,et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas , 2020, Nature Medicine.
[9] J. Bluestone,et al. The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28 , 2020, bioRxiv.
[10] Omer Dushek,et al. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function , 2020, Nature Communications.
[11] Weian Zhao,et al. CAR-T design: Elements and their synergistic function , 2020, EBioMedicine.
[12] A. Regev,et al. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] V. Ponomarev,et al. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. , 2020, Blood cancer discovery.
[14] S. Jagannath,et al. Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. , 2020 .
[15] A. McLellan,et al. Promoter choice: Who should drive the CAR in T cells? , 2020, bioRxiv.
[16] Jianhao Peng,et al. A single-cell gene regulatory network inference method for identifying complex regulatory dynamics across cell phenotypes , 2020, bioRxiv.
[17] J. Myklebust,et al. Tuning the Antigen Density Requirement for CAR T Cell Activity. , 2020, Cancer discovery.
[18] R. Flavell,et al. mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence , 2020, Science.
[19] Aviv Madar,et al. Single residue in CD28-costimulated CAR T cells limits long-term persistence and antitumor durability. , 2020, The Journal of clinical investigation.
[20] Wei-Ting Hwang,et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. , 2019, Blood advances.
[21] E. Wherry,et al. Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.
[22] Hui Hu,et al. Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL , 2019, Genom. Proteom. Bioinform..
[23] X. Bian,et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction , 2019, Nature.
[24] A. Yoshimura,et al. Nr4a transcription factors limit CAR T cell function in solid tumors , 2019, Nature.
[25] M. Sadelain,et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency , 2018, Nature Medicine.
[26] J. Maher,et al. Strategies to Address Chimeric Antigen Receptor Tonic Signaling , 2018, Molecular Cancer Therapeutics.
[27] J. Heath,et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. , 2018, Blood.
[28] C. Mackall,et al. Tumor Antigen Escape from CAR T-cell Therapy. , 2018, Cancer discovery.
[29] M. Sadelain,et al. Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.
[30] W. Fisher,et al. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. , 2018, Cancer discovery.
[31] G. Gaud,et al. Regulatory mechanisms in T cell receptor signalling , 2018, Nature Reviews Immunology.
[32] Hans Bitter,et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.
[33] A. Goldrath,et al. The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation. , 2018, Immunity.
[34] R. Hagedoorn,et al. A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies , 2018, Oncotarget.
[35] Z. Izsvák,et al. Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[37] J. Melenhorst,et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. , 2018, JCI insight.
[38] Stuart A. Sievers,et al. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[39] J. Orange,et al. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. , 2017, Cell reports.
[40] R. Orentas,et al. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[41] Benjamin D. Greenbaum,et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses , 2017, Cell.
[42] Mithat Gönen,et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.
[43] Rugang Zhang,et al. SATB1 Expression Governs Epigenetic Repression of PD‐1 in Tumor‐Reactive T Cells , 2017, Immunity.
[44] Kyle Bittinger,et al. INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions , 2016, Molecular therapy. Methods & clinical development.
[45] Kyle Bittinger,et al. INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes , 2016, Molecular therapy. Methods & clinical development.
[46] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[47] Howard Y. Chang,et al. Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution , 2016, Nature Genetics.
[48] Standley,et al. Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA , 2016, The Journal of experimental medicine.
[49] Brian Keith,et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.
[50] D. Maloney,et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.
[51] R. Kaplan,et al. 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors , 2015, Nature Medicine.
[52] Matthew J. Frigault,et al. Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells , 2015, Cancer Immunology Research.
[53] I. Amit,et al. Massively Parallel Single-Cell RNA-Seq for Marker-Free Decomposition of Tissues into Cell Types , 2014, Science.
[54] S. Holland,et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. , 2011, Immunity.
[55] S. Pai,et al. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation , 2009, Nature Reviews Immunology.
[56] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[57] J. Dausset,et al. In vivo, RFX5 binds differently to the human leucocyte antigen‐E, ‐F, and ‐G gene promoters and participates in HLA class I protein expression in a cell type‐dependent manner , 2004, Immunology.
[58] W. Reith,et al. A Functionally Essential Domain of RFX5 Mediates Activation of Major Histocompatibility Complex Class II Promoters by Promoting Cooperative Binding between RFX and NF-Y , 2000, Molecular and Cellular Biology.
[60] H. Einsele,et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors , 2017, Leukemia.
[61] D. Speiser,et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion , 2015, The EMBO journal.
[62] K. Anstey,et al. Cc-by-nc-nd 4.0 International License , 2022 .